Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.60 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.59 |
| ▸ | SRC | P12931 | 3/20 | 0.59 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.59 |
| ▸ | KIT | P10721 | 2/20 | 0.59 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.59 |
| ▸ | JAK3 | P52333 | 2/20 | 0.59 |
| ▸ | LCK | P06239 | 2/20 | 0.59 |
| ▸ | FYN | P06241 | 2/20 | 0.59 |
| ▸ | RET | P07949 | 2/20 | 0.59 |
| ▸ | MET | P08581 | 2/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.59 |
| ▸ | LTK | P29376 | 2/20 | 0.59 |
| ▸ | KDR | P35968 | 2/20 | 0.59 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.59 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.59 |
| ▸ | BTK | Q06187 | 2/20 | 0.59 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.59 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7236143 | 0.89 | EGFR (0.75) | EGFRERBB2ERBB4SRCAURKB | |
| SCHEMBL23450870 | 0.87 | EGFR (0.70) | EGFRERBB2ERBB4SRCAURKB | |
| SCHEMBL7237234 | 0.81 | EGFR (0.72) | EGFRERBB2ERBB4SRCAURKB | |
| SCHEMBL23450792 | 0.80 | EGFR (0.69) | EGFRERBB2ERBB4SRCAURKB | |
| SCHEMBL23450802 | 0.80 | EGFR (0.65) | EGFRERBB2ERBB4SRCAURKB | |
| SCHEMBL23451101 | 0.80 | EGFR (0.73) | EGFRERBB2ERBB4SRCAURKB | |
| SCHEMBL8525840 | 0.80 | EGFR (0.64) | EGFRERBB2ERBB4SRCAURKB | |
| SCHEMBL24751920 | 0.79 | EGFR (0.65) | EGFRERBB2ERBB4SRCAURKB | |
| SCHEMBL7234306 | 0.78 | EGFR (0.58) | EGFRERBB2ERBB4SRCAURKB | |
| SCHEMBL23450986 | 0.78 | SRC (0.61) | EGFRERBB2ERBB4SRCAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163447-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | BLACK DIAMOND THERAPEUTICS, INC. | 2021-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163447-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | ERBB2, ERBB3, EGFR | EGFR 3/4885ERBB2 1/4885ERBB4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.